N/A
Manufactured by Eisai Inc.
5,100 FDA adverse event reports analyzed
Last updated: 2026-04-15
RUFINAMIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Eisai Inc.. The most commonly reported adverse reactions for RUFINAMIDE include SEIZURE, DRUG INEFFECTIVE, OFF LABEL USE, SOMNOLENCE, DIARRHOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for RUFINAMIDE.
Out of 2,478 classified reports for RUFINAMIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 5,100 FDA FAERS reports that mention RUFINAMIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include SEIZURE, DRUG INEFFECTIVE, OFF LABEL USE, SOMNOLENCE, DIARRHOEA, CONDITION AGGRAVATED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Eisai Inc. in connection with RUFINAMIDE. Always verify the specific product and NDC with your pharmacist.